Roivant Sciences

Last updated
Roivant Sciences Ltd.
Company type Public
Industry Pharmaceuticals
FoundedApril 7, 2014;10 years ago (2014-04-07)
Founder Vivek Ramaswamy
Headquarters151 West 42nd Street
New York, NY 10036
U.S.
Key people
Matt Gline (CEO)
RevenueIncrease2.svg US$125 million (2024)
Increase2.svg US$4.24 billion (2024) [a]
Increase2.svg US$4.35 billion (2024) [a]
Total assets Increase2.svg US$7.22 billion (2024) [a]
Total equity Increase2.svg US$6.45 billion (2024) [a]
Owner Vivek Ramaswamy (10.5%)
Number of employees
908 (2024)
Website roivant.com
Footnotes /references
Financials as of 31 March 2024. [1] [2]

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. [3] Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

Contents

History

Vivek Ramaswamy founded Roivant in 2014. [4] Ramaswamy's initial strategy was to in-license drug candidates and create subsidiaries focused on distinct therapeutic areas. [5] This strategy expanded to include developing earlier stage drug candidates and platform technologies. Roivant is a parent company to over a dozen subsidiaries ranging from Immunovant, a majority-owned public company focused on autoimmune diseases, to privately held Dermavant Sciences, a commercial-stage company [6] focused on medical dermatology. [7]

Roivant also develops healthcare technologies through its business unit Roivant Health. Roivant built and launched Datavant, which allows healthcare institutions to share data, and was merged with Coix [8] to become a US$7 billion company. Roivant's technology portfolio also includes Lokavant, which integrates clinical trial data to identify and mitigate risks in pharmaceutical development. [7] [9] In 2017, Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant. [10] [11] [12] As of 2019, Roivant had over 40 investigational drugs in development in 14 therapeutic areas across its family of companies. [13]  

At the end of 2019, Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma and transferred its ownership stake in five of its subsidiaries: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences, which now sit under Sumitovant Biopharma. [14] The deal included the option for Sumitomo to acquire up to six additional subsidiaries. [15]

In April 2020, Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome (ARDS). [16] Additionally, in April, Datavant announced that its technology is being used to create a pro bono COVID-19 research database to help public health and policy researchers combat the pandemic. [17]

In January 2021, Ramaswamy stepped down as CEO. Matt Gline, previously the company's chief financial officer, became CEO. [18] In February 2021, Roivant acquired Silicon Therapeutics, a small-molecule drug designer and computational physics platform, for $450 million in Roivant equity. [19] [20] In October 2021, Roivant merged with special-purpose acquisition company Montes Archimedes Acquisition Corp. to become listed on the Nasdaq. [21]

In June 2022, Roivant and Pfizer unveiled Priovant Therapeutics. [22] Priovant was established in September 2021 through a transaction between Roivant and Pfizer, [23] in which Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant. Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results. Later that year in December 2022, Roivant and Pfizer announced [24] their third partnership to create a new Vant [25] focused on developing TL1A drug candidates for inflammatory and fibrotic diseases. As of February 2023, Roivant's reported market cap was over $6 billion. [26]

Axovant, owned by Roivant's Sio Gene Therapies, which failed testing in the end, has been accused of being a pump-and-dump scheme. [27] [28] [29] [30]

In December 2023, Roche completed the acquisition of Telavant from Roivant for a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. [31] [32]

Subsidiaries and former subsidiaries

As of April 2020, the company's subsidiaries include:

The following subsidiaries were previously a part of Roivant, but were included as part of a strategic transaction with Sumitomo Dainippon Pharma which closed in December 2019: [35]

Roivant is a major shareholder of Datavant, which was co-founded with Travis May to link disparate healthcare datasets. [43] In October 2020, Datavant announced it raised funds from Roivant alongside Transformation Capital, Johnson & Johnson, and Cigna. [44]

In June 2018, Roivant laid off 67 employees and reassigned 130 to subsidiaries. [45]

In March 2020, Roivant announced it is developing gimsilumab, an anti-granulocyte-macrophage colony-stimulating factor (anti-GM-CSF) monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19. [46] In April 2020, Roivant started the administration of gimsilumab to COVID-19 patients in the United States. [47]

Funding

The company received millions of dollars from hedge funds such as QVT in the early days of its existence. [48] Later, it was able to raise US$200 million, with help from NovaQuest Capital Management. [49]

PE/Growth round funding
YearAmount
2019
 
$1 billion
2018
 
$200 million
2017
 
$1.1 billion
2015
 
$500 million
2014
 
$93 million
Sources: [50] [4] [51]

Notes

  1. 1 2 3 4 Gain on sale of Telavant contributed $5.35bn. [1]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849, in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">AstraZeneca</span> British-Swedish pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. As one of the world's largest independent biotechnology companies, Amgen has approximately 24,000 staff in total as of 2022.

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd..

<span class="mw-page-title-main">Sumitomo Pharma</span> Pharmaceutical company based in Japan

Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.

<span class="mw-page-title-main">Santaris Pharma</span> Biopharmaceutical company founded in Denmark

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

Catalent, Inc., a subsidiary of Novo Holdings A/S since 2024, is a multinational corporation headquartered in Somerset, New Jersey. It is a provider of drug delivery technologies, drug development, drug manufacturing, biologics, gene therapy, and consumer health products. It has over 50 facilities on 4 continents and has supported more than half the products approved by the Food and Drug Administration in the last 10 years. Annually, it produces 70 billion doses for 8,000 products. The company's major customers include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics.

<span class="mw-page-title-main">Sio Gene Therapies</span> American pharmaceutical company

Sio Gene Therapies, Inc. was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party presidential primary candidate Vivek Ramaswamy in October 2014 as a wholly owned subsidiary of Roivant Sciences, which was itself founded in May 2014.

<span class="mw-page-title-main">Vivek Ramaswamy</span> American politician and entrepreneur (born 1985)

Vivek Ganapathy Ramaswamy is an American entrepreneur and politician. He founded Roivant Sciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared his candidacy for the Republican Party nomination in the 2024 United States presidential election. He suspended his campaign in January 2024, after finishing fourth in the Iowa caucuses and proceeded to endorse Trump's candidacy. On November 12, 2024, President-elect Donald Trump announced that Ramaswamy and businessman Elon Musk had been tasked to lead the newly proposed Department of Government Efficiency.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

<span class="mw-page-title-main">AION Labs</span>

AION Labs is an Israeli venture studio focused on the adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical discovery and development processes.

References

  1. 1 2 "FY 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 30 May 2024. Retrieved 16 June 2024.
  2. ↑ "2023 Proxy Statement". Archived from the original on 2023-09-02. Retrieved 2023-09-02.
  3. ↑ Hyatt, John (April 26, 2023). "How Rich Is Vivek Ramaswamy, The Longshot GOP Presidential Candidate Who Helped Take Down Don Lemon?". Forbes. Archived from the original on July 10, 2023. Retrieved July 10, 2023.
  4. 1 2 "Roivant Company Overview". Roivant Company Website.
  5. ↑ Spalding, Rebecca (13 November 2018). "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Archived from the original on 28 March 2019. Retrieved 20 February 2019.
  6. ↑ "Dermavant Sciences". Archived from the original on 2022-05-24. Retrieved 2023-02-22.
  7. 1 2 Loizos, Connie (14 November 2018). "Biotech holding company Roivant raised $200M in funding at a whopping $7B valuation". TechCrunch. Archived from the original on 25 September 2020. Retrieved 1 May 2020.
  8. ↑ Landi, Heather (June 9, 2021). "How Datavant's $7B deal with Ciox Health impacts the health data market". Fierece Healthcare. Archived from the original on 2023-03-31.
  9. ↑ "Roivant Sciences launches Lokavant for clinical trial monitoring". Clinical Trials Arena. 14 January 2020. Archived from the original on 20 October 2020. Retrieved 1 May 2020.
  10. ↑ Aronoff, Kate (2023-02-22). "GOP Presidential Candidate Vivek Ramaswamy, Who Used to Do Business With China, Wants to Ban Business With China". The New Republic . ISSN   0028-6583. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
  11. ↑ Keown, Alex (July 17, 2018). "Roivant Launches New China-Based Startup Sinovant Sciences". BioSpace. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
  12. ↑ Carroll, John (July 17, 2018). "Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline". Endpoints News. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
  13. ↑ Arnum, Patricia Van (16 October 2019). "Emerging Pharma: Roivant Sciences on the Rise". DCATVCI. Archived from the original on 2020-06-05. Retrieved 2020-06-05.
  14. 1 2 "On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant". BioSpace. Archived from the original on 2020-04-27. Retrieved 2020-03-18.
  15. ↑ "Roivant offloads biotech stakes in $3B alliance with Japanese pharma". BioPharma Dive. Archived from the original on 2020-10-28. Retrieved 2020-06-11.
  16. ↑ Tirumalaraju, Divya (16 April 2020). "Roivant starts gimsilumab dosing in Covid-19 trial". Clinical Trials Arena. Retrieved 14 January 2024.
  17. ↑ Haggin, Patience (2020-04-08). "Companies Seek to Pool Medical Records to Create Coronavirus Patient Registry". Wall Street Journal. ISSN   0099-9660. Archived from the original on 2020-06-26. Retrieved 2020-07-01.
  18. ↑ "Roivant's Ramaswamy Steps Down as CEO, Becomes Executive Chairman". BioSpace. Archived from the original on 2021-01-26. Retrieved 2021-01-28.
  19. ↑ "Roivant to absorb Silicon Therapeutics with $450M-plus deal". FierceBiotech. Archived from the original on 2021-04-19. Retrieved 2021-03-25.
  20. ↑ "Roivant Dives Deeper into AI with $450 Million Buy of Silicon Therapeutics". BioSpace. Archived from the original on 2021-02-27. Retrieved 2021-03-25.
  21. ↑ "Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology" (Press release). PR Newswire. May 3, 2021. Archived from the original on October 3, 2021. Retrieved October 3, 2021.
  22. ↑ Taylor, Nick Paul (Jun 28, 2022). "Roivant is Pfizer's TYK2 partner". Fierce Biotech. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
  23. ↑ "Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus". Roivant. June 28, 2022. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
  24. ↑ "Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases". Roivant. December 1, 2022. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
  25. ↑ Satija, Bhanvi; Mandowara, Khushi; Satija, Bhanvi (December 1, 2022). "Roivant, Pfizer team up on inflammatory disease drug". Reuters. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
  26. ↑ Out of Ignorance (6 March 2023). "Roivant Sciences: Fiercely Economic Actor with Multiple Catalysts". Seeking Alpha. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
  27. ↑ Sonnenfeld, Jeffrey (August 31, 2023). "Smoke and mirrors: I've been debating Vivek Ramaswamy for 2 years. Here's how I got past his diversionary tactics". Fortune. Archived from the original on 2023-09-05. Retrieved 2023-09-05.
  28. ↑ Sonnenfeld, Jeffrey; Tian, Steven (June 14, 2023). "Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype". Fortune. Archived from the original on 2023-09-05. Retrieved 2023-09-05.
  29. ↑ Piper, Jessica (14 May 2023). "How Vivek Ramaswamy made a fortune before pivoting to politics". Politico . Archived from the original on 2023-06-29. Retrieved 2023-09-05.
  30. ↑ Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (27 June 2023). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run" . The New York Times. Archived from the original on 2023-06-29. Retrieved 2023-09-05.
  31. ↑ "Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease". Yahoo Finance. 2023-12-14. Retrieved 2024-04-05.
  32. ↑ "Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal". Reuters . Retrieved 2024-04-05.
  33. ↑ Carroll, John. "Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets". Endpoints News. Archived from the original on 13 November 2018. Retrieved 31 October 2018.
  34. ↑ Keown, Alex. "Roivant Taps Genentech Veteran". BioSpace. Archived from the original on 13 November 2018. Retrieved 31 October 2018.
  35. ↑ "Sumitomo Dainippon and Roivant Close Deal to Form Sumitovant Biopharma". BioSpace. Archived from the original on 2020-03-25. Retrieved 2020-03-25.
  36. ↑ Henderson, Jennifer. "Changes and headcount reduction at Roivant, but hiring expected in Durham". Bizjournals. Archived from the original on 27 September 2023. Retrieved 7 January 2019.
  37. ↑ "Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis". GlobeNewswire News Room (Press release). Dermavant Sciences Inc. 2019-06-05. Archived from the original on 2019-06-12. Retrieved 2020-03-18.
  38. ↑ "Organon to buy Roivant's dermatology unit for up to $1.2 billion". Reuters. 18 September 2024.
  39. ↑ Adams, Ben. "Roivant and Plexcera launch rare disease-focused spinout". Fierce Biotech. Archived from the original on 2016-10-11. Retrieved 2016-10-07.
  40. ↑ Leuty, Ron (27 October 2016). "Biggest biotech IPO this year is a small Peninsula company". San Francisco Business Times. Archived from the original on 12 November 2016. Retrieved 14 November 2016.
  41. ↑ Pagliarulo, Ned. "Roivant, Sumitomo alliance to target cystic fibrosis gene therapy". BioPharma Dive. Archived from the original on 12 November 2019. Retrieved 12 November 2019.
  42. ↑ Adams, Ben (June 7, 2017). "Roivant launches Urovant with phase 3 Merck med". FierceBiotech. Archived from the original on August 7, 2017. Retrieved August 7, 2017.
  43. ↑ Carroll, John. "Tech maven Travis May takes the helm of Roivant's data mining startup". Endpoints News. Archived from the original on 8 November 2018. Retrieved 18 November 2018.
  44. ↑ ""Datavant Raises $40 Million in Series B Financing to Expand Open Health Data Ecosystem"" (Press release). Archived from the original on 2020-10-15. Retrieved 2020-10-13.
  45. ↑ Taylor, Nick Paul. "Roivant cuts staff, reassigns others in a major reshuffle, as insider decries 'bloodbath'". Archived from the original on 2018-07-05. Retrieved 2018-07-04.
  46. ↑ "Roivant pivots towards ARDS in COVID-19". BioCentury. Archived from the original on 2020-08-15. Retrieved 2020-04-02.
  47. ↑ "Roivant Begins Giving Experimental COVID-19 Drug to First U.S. Patients". The New York Times. Reuters. 2020-04-15. ISSN   0362-4331 . Retrieved 2020-04-23.
  48. ↑ Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN   0362-4331. Archived from the original on 2023-06-29. Retrieved 2023-09-13. In 2014, Mr. Ramaswamy founded Roivant Sciences — incorporated in the tax haven of Bermuda and backed by nearly $100 million in funding from investors including QVT, a hedge fund that employed Mr. Ramaswamy after college.
  49. ↑ Loizos, Connie (2018-11-14). "Biotech holding company Roivant Sciences raised $200M in funding at a whopping $7B valuation". TechCrunch. Archived from the original on 2023-04-18. Retrieved 2023-09-13.
  50. ↑ "Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank". TechCrunch. Archived from the original on 2018-11-06. Retrieved 2018-11-06.
  51. ↑ Spalding, Rebecca (13 November 2018). "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Archived from the original on 6 December 2018. Retrieved 5 December 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.